Want to see BOLT full AI Analyst Report?
BOLT Stock Chart & Stats
$4.73
-$0.02(-3.16%)
At close: 4:00 PM EST
$4.73
-$0.02(-3.16%)
Day’s Range― - ―
52-Week Range$3.75 - $7.20
Previous CloseN/A
Volume72.19K
Average Volume (3M)29.18K
Market Cap
$7.26M
Enterprise Value$18.79M
Total Cash (Recent Filing)$22.89M
Total Debt (Recent Filing)$22.31M
Price to Earnings (P/E)―
Beta0.43
Next Earnings
Aug 12, 2026EPS Estimate
-3.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-15.89
Shares Outstanding1,921,567
10 Day Avg. Volume31,146
30 Day Avg. Volume29,181
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.33
P/FCF Ratio-0.26
Enterprise Value/Market Cap2.59
Enterprise Value/Revenue2.89
Enterprise Value/Gross Profit2.98
Enterprise Value/Ebitda-0.66
Forecast
1Y Price Target
$34.67Price Target Upside632.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-14.43
Revenue Forecast (FY)$1.51M
Bulls Say, Bears Say
Bulls Say
Proprietary PlatformBolt's proprietary Boltbody platform is a durable fundamental strength: platform technologies can generate multiple development candidates, support follow-on indications, and attract partnership economics. Structural value arises from repeatable R&D processes and potential licensing opportunities beyond any single asset.
Improved Gross MarginMaterial improvement in gross margin is a lasting operational positive: it suggests improving cost efficiencies or favorable program economics that can scale with commercialization. Higher gross margins enhance the potential for sustainable profitability once revenues mature and reduce future funding pressure.
Governance ContinuityBoard continuity and an established independent auditor strengthen corporate governance and oversight. For a clinical-stage biotech, consistent governance reduces execution risk, supports strategic decision-making, and aids credibility with partners and investors during capital raises and long development timelines.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow is a durable weakness: continuous cash burn necessitates repeated capital raises or dilutive financing, constraining strategic flexibility. This pressure can divert management attention, limit long-term program funding, and increase execution risk during multi-year clinical development.
Very Small, Declining RevenueMinimal and falling revenue indicates lack of commercial scale and heavy reliance on collaborations or financing. As a structural point, limited recurring product sales mean the company cannot self-fund advancement, increasing dependence on external partners and capital markets to sustain long-term R&D and regulatory pathways.
Rising Leverage & Shrinking EquityIncreasing leverage and reduced equity are persistent balance-sheet constraints: higher debt-to-equity limits financial flexibility, raises refinancing risk, and can increase cost of capital. For a loss-making biotech, this structural weakness reduces runway and bargaining power for partnerships or licensing deals.
Bolt Biotherapeutics News
BOLT FAQ
What was Bolt Biotherapeutics’s price range in the past 12 months?
Bolt Biotherapeutics lowest stock price was $3.75 and its highest was $7.20 in the past 12 months.
What is Bolt Biotherapeutics’s market cap?
Bolt Biotherapeutics’s market cap is $7.26M.
When is Bolt Biotherapeutics’s upcoming earnings report date?
Bolt Biotherapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 31 days.
How were Bolt Biotherapeutics’s earnings last quarter?
Bolt Biotherapeutics released its earnings results on May 12, 2026. The company reported -$4.31 earnings per share for the quarter, missing the consensus estimate of -$2.85 by -$1.46.
Is Bolt Biotherapeutics overvalued?
According to Wall Street analysts Bolt Biotherapeutics’s price is currently Undervalued.
Does Bolt Biotherapeutics pay dividends?
Bolt Biotherapeutics pays a Quarterly dividend of $0.09 which represents an annual dividend yield of N/A. See more information on Bolt Biotherapeutics dividends here
What is Bolt Biotherapeutics’s EPS estimate?
Bolt Biotherapeutics’s EPS estimate is -3.39.
How many shares outstanding does Bolt Biotherapeutics have?
Bolt Biotherapeutics has 1,921,567 shares outstanding.
What happened to Bolt Biotherapeutics’s price movement after its last earnings report?
Bolt Biotherapeutics reported an EPS of -$4.31 in its last earnings report, missing expectations of -$2.85. Following the earnings report the stock price went up 1.046%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics?
Currently, no hedge funds are holding shares in BOLT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bolt Biotherapeutics
Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.
BOLT Stock 12 Month Forecast
Average Price Target
$34.67
▲(632.91% Upside)
Technical Analysis
Ownership Overview
2.28% Insiders
3.97% Mutual Funds
23.96% Other Institutional Investors
69.42% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---